Across TCGA pan-cancer cohorts, IPO7P2 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated IPO7P2 data layer.
The strongest signal is observed in mesothelioma (MESO), where higher IPO7P2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated IPO7P2 expression acts as an unfavorable survival marker, although some lineages such as KIRC and READ show a favorable association.
MESO, KIRC, and PAAD are the cancer types where IPO7P2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.